AIPLMC ASSOCIAZIONE ITALIANA PAZIENTI LEUCEMIA MIELOIDE CRONICA - APS

Evaluation of the therapeutic activity and of the cardiovascular safety profile of Ponatinib when used as treatment option of Chronic Myeloid Leukemia (CML) in Chronic Phase (CP), after failure of therapy with Imatinib and Bosutinib.